Solis v. Millennium Pharmaceuticals, Inc., 445 F.Supp.3d 786

Background:

Relator Frank Solis, a former sales representative for Millennium, Schering‑Plough, and Merck, sued under the FCA alleging off‑label promotion of Integrilin and unlawful kickbacks (also limited allegations about Avelox) that caused false claims to Medicare, Medicaid, and TRICARE.
The United States and multiple states declined to intervene; the case was originally filed in 2009 and unsealed in 2012 after a multi‑year investigation.
Defendants moved to dismiss under Rule 12(b)(1) arguing the FCA public‑disclosure bar applies and Solis is not an "original source;" Schering also moved to dismiss Avelox claims under Rules 12(b)(6) and 9(b).
The district court previously dismissed portions of earlier complaints, the Ninth Circuit affirmed that Integrilin allegations were substantially similar to prior public disclosures but remanded to assess "original source" status under Hartpence, and affirmed that Avelox claims lacked Rule 9(b) particularity.
On remand Solis filed a Third Amended Complaint attempting to address original‑source and Avelox pleading defects; the district court held Solis still lacked direct, independent knowledge of actual false claims (no specific false claims or patients identified) and that Avelox allegations remained deficient.
The court granted Defendants’ 12(b)(1) motions (dismissing federal FCA claims and declining supplemental jurisdiction over related state claims), and granted Schering’s 9(b) motion as to Avelox; dismissal was without further leave to amend.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether the FCA public‑disclosure bar deprives the court of jurisdiction over Integrilin allegations	Solis says he is an "original source" with direct and independent knowledge from his employment, trainings, communications, and interactions with physicians	Defendants say Integrilin allegations were publicly disclosed earlier and Solis lacks direct, independent knowledge of actual false claims submitted	Held: Public‑disclosure bar applies; Solis is not an original source for Integrilin allegations; 12(b)(1) dismissal granted
Whether Solis has direct, independent knowledge that false claims were submitted (required for original‑source status)	Solis points to company trainings, MSL letters, sales plans, and observed promotional activities as firsthand knowledge that would show resulting false claims	Defendants argue those materials and observations do not show any actual false claims or identify any claims/patients; employment alone is insufficient	Held: Insufficient — Solis failed to identify any specific false claim or evidence that claims resulted from the alleged scheme; conclusory allegations do not meet the standard
Whether kickback/off‑label allegations plausibly show claims were ineligible for reimbursement	Solis contends off‑label promotion and meals/honoraria incentivized prescriptions that necessarily produced false claims	Defendants respond off‑label use can be medically reasonable (not per se non‑reimbursable) and Solis offers no quid pro quo evidence tying payments to specific prescriptions/claims	Held: Insufficient to show false claims submission; speculation that claims "must have been submitted" is inadequate
Whether Avelox allegations satisfy Rule 9(b) particularity	Solis attempted to add a spreadsheet and a paragraph about formulary targeting to cure prior defects	Defendants say the new allegations still fail to identify any particular false claim or provide reliable indicia that claims were submitted	Held: Avelox claims remain deficient under Rule 9(b); dismissal granted without leave to amend

Key Cases Cited

Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375 (1994) (federal courts are courts of limited jurisdiction)
Rockwell Int'l Corp. v. United States, 549 U.S. 457 (2007) (FCA public‑disclosure bar limits jurisdiction)
Hartpence v. Kinetic Concepts, Inc., 792 F.3d 1121 (9th Cir. 2015) (en banc) (original‑source test requires direct and independent knowledge)
United States ex rel. Meyer v. Horizon Health Corp., 565 F.3d 1195 (9th Cir. 2009) (distinguishing knowledge of fraud from direct knowledge of fraudulent billing)
United States ex rel. Aflatooni v. Kitsap Physicians Servs., 163 F.3d 516 (9th Cir. 1998) (former employee must identify specific false claims to qualify as original source)
Ebeid ex rel. U.S. v. Lungwitz, 616 F.3d 993 (9th Cir. 2010) (FCA fraud pleadings require "who, what, when, where, and how")
Cafasso v. General Dynamics C4 Sys., Inc., 637 F.3d 1047 (9th Cir. 2011) (an actual false claim is the core of an FCA violation)
United States ex rel. Solis v. Millennium Pharm., Inc., 885 F.3d 623 (9th Cir. 2018) (Ninth Circuit affirmed public‑disclosure finding, remanded original‑source question, and affirmed Rule 9(b) dismissal of Avelox claims)
Clausen v. Laboratory Corp. of Am., 290 F.3d 1301 (11th Cir. 2002) (courts require particularized allegations and reliable indicia that claims were submitted)
Foman v. Davis, 371 U.S. 178 (1962) (leave to amend should be freely given absent futility, prejudice, or bad faith)